Last reviewed · How we verify
Rosuvastatin Oral Tablet
At a glance
| Generic name | Rosuvastatin Oral Tablet |
|---|---|
| Sponsor | Washington State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) (PHASE3)
- A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039) (PHASE1)
- A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia (PHASE2)
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (PHASE1)
- Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants (PHASE1)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia (PHASE2, PHASE3)
- A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together (PHASE1)
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosuvastatin Oral Tablet CI brief — competitive landscape report
- Rosuvastatin Oral Tablet updates RSS · CI watch RSS
- Washington State University portfolio CI